Historic Mapping Of Deadly Pathogens Allows PacBio To Showcase Its Platform
PacBio and Wellcome Sanger Institute tell Scrip why they've teamed up to decode genomes of more than 3,000 bacteria, including some of the world's most dangerous, and how it will help fight AMR and bioterrorism.
You may also be interested in...
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.